111 related articles for article (PubMed ID: 19942938)
1. Ocular adnexal diffuse large B-cell lymphoma: local disease correlates with better outcomes.
Madge SN; McCormick A; Patel I; Hatef E; Menon V; Prabhakaran VC; Irion L; Bonshek R; Honovar S; Leatherbarrow B; Esmaeli B; Selva D
Eye (Lond); 2010 Jun; 24(6):954-61. PubMed ID: 19942938
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.
Stacy RC; Jakobiec FA; Herwig MC; Schoenfield L; Singh A; Grossniklaus HE
Am J Ophthalmol; 2012 Jul; 154(1):87-98.e1. PubMed ID: 22503694
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma of the ocular adnexal region: a nation-based study.
Rasmussen PK; Ralfkiaer E; Prause JU; Sjö LD; Toft PB; Siersma VD; Heegaard S
Acta Ophthalmol; 2013 Mar; 91(2):163-9. PubMed ID: 22551232
[TBL] [Abstract][Full Text] [Related]
5. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic significance of Skp2 and p27(kip) in diffuse large B cell lymphoma].
Seki R; Ohshima K; Okamura T
Rinsho Ketsueki; 2010 Dec; 51(12):1741-7. PubMed ID: 21258183
[No Abstract] [Full Text] [Related]
7. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
Li D; Xie P; Mi C
Pathol Res Pract; 2010 Sep; 206(9):611-5. PubMed ID: 20627604
[TBL] [Abstract][Full Text] [Related]
8. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
9. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
10. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
Morley AM; Verity DH; Meligonis G; Rose GE
Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
[TBL] [Abstract][Full Text] [Related]
11. [Clinical analysis of primary gastric diffuse large B-cell lymphoma].
Zhang J; Wang MY; Xu LC; Gu SY; Cao JN; Hu XC; Hong XN
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):614-8. PubMed ID: 21122416
[TBL] [Abstract][Full Text] [Related]
12. Primary high-grade ocular adnexal lymphoma: clinicopathological characteristics and prognostic factors of a single-centre series.
Precupanu CM; Validire P; Lévy C; Plancher C; Vincent-Salomon A; Dendale R; Asselain B; Servois V; Desjardins L; Zanni M; Sahli R; Lumbroso-le Rouic L; Decaudin D
Am J Hematol; 2010 May; 85(5):372-5. PubMed ID: 20309854
[No Abstract] [Full Text] [Related]
13. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
Zinzani PL; Broccoli A; Stefoni V; Musuraca G; Abruzzese E; De Renzo A; Cantonetti M; Bacci F; Baccarani M; Pileri SA
Cancer; 2010 Dec; 116(24):5667-75. PubMed ID: 20737566
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Ninomiya S; Hara T; Tsurumi H; Hoshi M; Kanemura N; Goto N; Kasahara S; Shimizu M; Ito H; Saito K; Hirose Y; Yamada T; Takahashi T; Seishima M; Takami T; Moriwaki H
Ann Hematol; 2011 Apr; 90(4):409-16. PubMed ID: 20938662
[TBL] [Abstract][Full Text] [Related]
15. Lymphoproliferative diseases of the ocular adnexa in Korea.
Oh DE; Kim YD
Arch Ophthalmol; 2007 Dec; 125(12):1668-73. PubMed ID: 18071120
[TBL] [Abstract][Full Text] [Related]
16. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.
Hallermann C; Niermann C; Fischer RJ; Schulze HJ
J Am Acad Dermatol; 2007 Apr; 56(4):588-97. PubMed ID: 17289214
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
19. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
20. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases.
Coupland SE; Krause L; Delecluse HJ; Anagnostopoulos I; Foss HD; Hummel M; Bornfeld N; Lee WR; Stein H
Ophthalmology; 1998 Aug; 105(8):1430-41. PubMed ID: 9709754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
